Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
1.
Biomedicines ; 11(7)2023 Jun 22.
Article in English | MEDLINE | ID: mdl-37509431

ABSTRACT

Diabetic retinopathy (DR) is the major microvascular complication of diabetes and causes vitreous traction and intraretinal hemorrhages leading to retinal detachment and total blindness. The evolution of diabetes is related to exacerbating inflammation caused by hyperglycemia and activation of inflammatory cells. Neutrophils are cells able to release structures of extracellular DNA and proteolytic enzymes called extracellular traps (NETs), which are associated with the persistence of inflammation in chronic pathologies. The purpose of the study was to determine the usefulness of neutrophil traps as indicators of DR progression in patients with type 2 diabetes (T2DM). We performed a case-control study of seventy-four cases classified into five groups (non-proliferative DR, mild, moderate, severe, and proliferative) and fifteen healthy controls. We found correlations between NETs and a diagnostic time of T2DM (r = 0.42; p < 0.0001), fasting glucose (r = 0.29; p < 0.01), glycated hemoglobin (HbA1c) (r = 0.31; p < 0.01), estimated glomerular filtration rate (eGFR) (r = -0.29; p < 0.01), and plasma osmolarity (r = 0.25; p < 0.01). These results suggest that due to NETs being associated with clinical indicators, such as HbA1c and eGFR, and that NETs are also associated with DR, clinical indicators might be explained in part through an NET-mediated inflammation process.

2.
Ophthalmic Epidemiol ; 30(4): 400-406, 2023 08.
Article in English | MEDLINE | ID: mdl-36184872

ABSTRACT

OBJECTIVE: In this study, we investigated the impact of the SARS-CoV-2 vaccination on seroprevalence in a cohort of healthcare workers (HCW) at an ophthalmic medical center. METHODS: IgG antibodies against the N, S1, and S2 antigens of SARS-CoV-2 as well as their serum neutralizing activity were determined. RESULTS: In the present study, we observed that 98.4% of HCW were seropositive for S1/S2 proteins of SARS-CoV-2 due to the national vaccination program. Interestingly, 78.4% of the participants had anti-N protein antibodies, suggesting previous COVID-19 infection. We also evaluated the neutralizing antibodies and found that the mean value was high (90.7%). CONCLUSION: These results indicate that our HCWs cohort presented a robust hybrid humoral response owing to the massive national vaccination program and natural infections.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , Pandemics , Seroepidemiologic Studies , COVID-19 Vaccines , Health Personnel
3.
Cells ; 11(18)2022 09 10.
Article in English | MEDLINE | ID: mdl-36139406

ABSTRACT

Human amniotic membrane mesenchymal stem cells (hAM-MSC) secrete a myriad of components with immunosuppressive activities. In the present research, we aimed to describe the effect of prostaglandin E2 (PGE2) secreted by hAM-MSCs on neutrophil extracellular trap (NET) release and to characterize the role of its receptors (EP2/EP4) in PAD-4 and NFκB activity in neutrophils. Human peripheral blood neutrophils were ionomycin-stimulated in the presence of hAM-MSC conditioned medium (CM) treated or not with the selective PGE2 inhibitor MF-63, PGE2, EP2/EP4 agonists, and the selective PAD-4 inhibitor GSK-484. NET release, PAD-4, and NFκB activation were analyzed. Ionomycin induced NET release, which was inhibited in the presence of hAM-MSC-CM, while CM from hAM-MSCs treated with MF-63 prevented NET release inhibition. PGE2 and EP2/EP4 agonists, and GSK-484 inhibited NET release. EP2/EP4 agonists and GSK-484 inhibited H3-citrullination but did not affect PAD-4 protein expression. Finally, PGE2 and EP2/EP4 agonists and GSK-484 increased NFκB phosphorylation. Taken together, these results suggest that hAM-MSC exert their immunomodulatory activities through PGE2, inhibiting NET release in a PAD-4-dependent pathway. This research proposes a new mechanism by which hAM-MSC exert their activities when modulating the innate immune response and inhibiting NET release.


Subject(s)
Extracellular Traps , Mesenchymal Stem Cells , Amnion/metabolism , Culture Media, Conditioned/pharmacology , Dinoprostone/metabolism , Dinoprostone/pharmacology , Extracellular Traps/metabolism , Humans , Ionomycin , Mesenchymal Stem Cells/metabolism , Receptors, Prostaglandin E, EP2 Subtype , Receptors, Prostaglandin E, EP4 Subtype/metabolism
4.
Int J Mol Sci ; 22(23)2021 Dec 05.
Article in English | MEDLINE | ID: mdl-34884955

ABSTRACT

Proliferative retinopathies produces an irreversible type of blindness affecting working age and pediatric population of industrialized countries. Despite the good results of anti-VEGF therapy, intraocular and systemic complications are often associated after its intravitreal use, hence novel therapeutic approaches are needed. The aim of the present study is to test the effect of the AS1411, an antiangiogenic nucleolin-binding aptamer, using in vivo, ex vivo and in vitro models of angiogenesis and propose a mechanistic insight. Our results showed that AS1411 significantly inhibited retinal neovascularization in the oxygen induced retinopathy (OIR) in vivo model, as well as inhibited branch formation in the rat aortic ex vivo assay, and, significantly reduced proliferation, cell migration and tube formation in the HUVEC in vitro model. Importantly, phosphorylated NCL protein was significantly abolished in HUVEC in the presence of AS1411 without affecting NFκB phosphorylation and -21 and 221-angiomiRs, suggesting that the antiangiogenic properties of this molecule are partially mediated by a down regulation in NCL phosphorylation. In sum, this new research further supports the NCL role in the molecular etiology of pathological angiogenesis and identifies AS1411 as a novel anti-angiogenic treatment.


Subject(s)
Aptamers, Nucleotide/administration & dosage , Oligodeoxyribonucleotides/administration & dosage , Oxygen/adverse effects , Phosphoproteins/metabolism , RNA-Binding Proteins/metabolism , Retinal Neovascularization/drug therapy , Animals , Aptamers, Nucleotide/pharmacology , Cell Movement/drug effects , Cell Proliferation/drug effects , Disease Models, Animal , Gene Expression Regulation/drug effects , Human Umbilical Vein Endothelial Cells , Humans , Intravitreal Injections , Mice , MicroRNAs/genetics , Oligodeoxyribonucleotides/pharmacology , Phosphoproteins/antagonists & inhibitors , Phosphoproteins/genetics , Phosphorylation/drug effects , RNA-Binding Proteins/antagonists & inhibitors , RNA-Binding Proteins/genetics , Retinal Neovascularization/chemically induced , Retinal Neovascularization/genetics , Retinal Neovascularization/metabolism , Nucleolin
5.
Rev. colomb. cardiol ; 2(1): 27-9, mayo 1986. ilus
Article in Spanish | LILACS | ID: lil-219252

ABSTRACT

Se presenta el caso de un niño de 36 días con el diagnóstico de Cardiopatía Congénita Cianógena. A la edad de 7 días tuvo una derivación ventriculoatrial por hidrocefália asociada a menigocele lumbar. Con ecocardiografía se estableció el diagnóstico de masa en aurícula derecha y, con técnica de contraste, el de flujo de derecha a izquierda, debido a obstrucción tricuspidea. Después de retirar el catéter y bajo dos períodos de oclusión de cavas, se extrajeron abundantes vegetaciones y material purulento de la aurícula derecha con recuperación del niño


Subject(s)
Humans , Male , Infant, Newborn , Heart Defects, Congenital/diagnosis , Heart Defects, Congenital/therapy , Cardiopulmonary Bypass , Cerebrospinal Fluid Shunts , Heart Neoplasms/diagnosis , Heart Neoplasms/surgery , Meningocele
SELECTION OF CITATIONS
SEARCH DETAIL
...